-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pharmaceutical Network News, August 20, on the evening of August 19, Hengrui Pharmaceuticals released the 2021 semi-annual report.
The report showed that Hengrui Pharmaceuticals invested more than 2.
58 billion yuan in R&D in the first half of this year, an increase of 38.
48% year-on-year, and the proportion of R&D investment in sales revenue reached 19.
41%, a record high
.
The report showed that Hengrui Pharmaceuticals invested more than 2.
58 billion yuan in R&D in the first half of this year, an increase of 38.
48% year-on-year, and the proportion of R&D investment in sales revenue reached 19.
41%, a record high
.
At the same time, in this financial report, Hengrui Pharmaceuticals fully disclosed its latest product pipeline, covering the main clinical R&D pipelines of listed innovative drugs, the main clinical R&D pipelines of innovative drugs under research, and the main clinical R&D pipelines of overseas innovative drugs.
More than 240 clinical projects have been carried out at home and abroad,” and other information has attracted the attention of the industry
.
More than 240 clinical projects have been carried out at home and abroad,” and other information has attracted the attention of the industry
.
In the first half of this year, Hengrui Pharmaceuticals officially entered a critical transition period for the business sector to migrate from generic drugs to innovative drugs
.
After experiencing the decline in the sales of generic drugs purchased in large quantities and the heavy test of innovative drugs and medical insurance negotiations, Sun Piaoyang took charge of the “second time”.
The industry is very concerned about the next development trend of Hengrui Medicine.
The product pipeline shown in the content of the semi-annual report With investment in research and development, the market has already made the market feel the determination of Hengrui Pharmaceuticals in the new stage of innovation and internationalization
.
.
After experiencing the decline in the sales of generic drugs purchased in large quantities and the heavy test of innovative drugs and medical insurance negotiations, Sun Piaoyang took charge of the “second time”.
The industry is very concerned about the next development trend of Hengrui Medicine.
The product pipeline shown in the content of the semi-annual report With investment in research and development, the market has already made the market feel the determination of Hengrui Pharmaceuticals in the new stage of innovation and internationalization
.
Hengrui's "drawer" is opening
"Whether it is a small molecule or a large molecule, Hengrui's innovative drugs are far ahead in terms of the number of research and development and the speed of clinical advancement.
More importantly, you can't guess how much Sun Piaoyang and Hengrui have hidden in their drawers.
New medicine!" At the end of 2020, the market value of Hengrui Pharmaceuticals exceeded 600 billion yuan.
At a medical innovation research and development conference, a guest expressed such emotion
.
More importantly, you can't guess how much Sun Piaoyang and Hengrui have hidden in their drawers.
New medicine!" At the end of 2020, the market value of Hengrui Pharmaceuticals exceeded 600 billion yuan.
At a medical innovation research and development conference, a guest expressed such emotion
.
When it comes to the transformation and upgrading of local medicines and R&D innovation, Hengrui Pharmaceuticals is an existence that cannot be ignored
.
However, in 2021, faced with the pressure of high-volume procurement competition and the "clinical value" of local pharmaceutical innovation, Hengrui's stock price fluctuated and dropped, and its market value evaporated by more than 200 billion yuan in just six months
.
.
However, in 2021, faced with the pressure of high-volume procurement competition and the "clinical value" of local pharmaceutical innovation, Hengrui's stock price fluctuated and dropped, and its market value evaporated by more than 200 billion yuan in just six months
.
Today, the entire industry is undergoing the test of ecological changes in the pharmaceutical industry and adapting to the new market rules under the new normal
.
Facing the fierce competition brought about by the normalization of mass purchases, the medical insurance payment system reform and the pressure of increasing the volume of drugs after price negotiations , many pharmaceutical companies are facing the same market pressure as Hengrui Pharmaceuticals
.
.
Facing the fierce competition brought about by the normalization of mass purchases, the medical insurance payment system reform and the pressure of increasing the volume of drugs after price negotiations , many pharmaceutical companies are facing the same market pressure as Hengrui Pharmaceuticals
.
As described by Hengrui Medicine in this semi-annual report, since 2018, the company has entered the country to purchase a total of 28 varieties of generic drugs.
18 varieties have been selected.
The average price of the selected products has dropped by 72.
6%, which has caused the company's performance.
Greater pressure
.
At the same time, the domestic innovative biopharmaceutical industry is facing serious homogeneity competition, and the costs of research and development, manpower, and production are rising rapidly, and biomedical innovation is facing severe challenges
.
18 varieties have been selected.
The average price of the selected products has dropped by 72.
6%, which has caused the company's performance.
Greater pressure
.
At the same time, the domestic innovative biopharmaceutical industry is facing serious homogeneity competition, and the costs of research and development, manpower, and production are rising rapidly, and biomedical innovation is facing severe challenges
.
As a leader in the transformation and innovation and upgrading of China's pharmaceutical industry, concentrating resources to achieve rapid breakthroughs in innovation and internationalization is a solution considered by Hengrui Pharmaceuticals and an inevitable choice for the medium and long-term development of the company
.
.
In fact, Hengrui Pharmaceutical’s annual R&D investment in 2020 will be close to 5 billion yuan, and the proportion of R&D in revenue is rapidly approaching the level of multinational pharmaceutical companies.
According to the current rhythm of R&D and innovation of enterprises, large-scale R&D investment continues to promote, so Hengrui Medicine achieved results in the first half of this year
.
According to the current rhythm of R&D and innovation of enterprises, large-scale R&D investment continues to promote, so Hengrui Medicine achieved results in the first half of this year
.
The semi-annual report shows that in the first half of this year, Hengrui Pharmaceuticals obtained 5 production approvals for innovative drug preparations, 9 production approvals for generic pharmaceutical preparations, 41 drug clinical approvals, and obtained consistency evaluation approvals for 10 varieties, and completed the agreement of 2 products.
More than 240 clinical projects are being carried out at home and abroad; 131 new domestic patent applications and 39 new international PCT applications have been submitted, 64 domestic authorizations and 59 foreign authorizations have been obtained
.
More than 240 clinical projects are being carried out at home and abroad; 131 new domestic patent applications and 39 new international PCT applications have been submitted, 64 domestic authorizations and 59 foreign authorizations have been obtained
.
Speed up the process of internationalization
Focusing on the topic of the internationalization of China’s pharmaceutical industry, Chinese companies and pharmaceutical products must not only “bring in” but also “go out”.
How to sell outstanding Chinese-developed drugs to overseas markets is something that large domestic pharmaceutical companies are thinking about.
And explore the development path
.
How to sell outstanding Chinese-developed drugs to overseas markets is something that large domestic pharmaceutical companies are thinking about.
And explore the development path
.
Internationalization is the strategic direction Hengrui has adhered to for many years
.
In the first half of this year, Hengrui Medicine’s overseas R&D expenditure totaled 643 million yuan, and the pace of building an international clinical R&D team and deploying international clinical trials of innovative drugs has been accelerating
.
The company has established a complete clinical R&D team covering medical science, clinical operations, registration, pharmacology, statistics, quality management, pharmacovigilance and other departments in the United States and Europe, and has achieved high-efficiency operation and high-quality execution of research projects At present, the company has a total of 136 overseas R&D teams, including 95 in the US team and 31 in the European team
.
.
In the first half of this year, Hengrui Medicine’s overseas R&D expenditure totaled 643 million yuan, and the pace of building an international clinical R&D team and deploying international clinical trials of innovative drugs has been accelerating
.
The company has established a complete clinical R&D team covering medical science, clinical operations, registration, pharmacology, statistics, quality management, pharmacovigilance and other departments in the United States and Europe, and has achieved high-efficiency operation and high-quality execution of research projects At present, the company has a total of 136 overseas R&D teams, including 95 in the US team and 31 in the European team
.
In terms of specific projects, in the first half of this year, Hengrui Medicine received 3 FDA clinical approvals, including fluzoparib capsules combined with abiraterone acetate tablets and prednisone tablets (AA-P) compared to placebo combined with AA-P as first-line treatment An international multi-center phase III study of metastatic castration-resistant prostate cancer, a multi-cohort, open phase II study of carrelizumab combined with famitinib in the treatment of advanced solid tumors, and evaluation of the pharmacodynamics of HR17031 injection, Phase I study of pharmacokinetics, safety and tolerability
.
The first international multi-center phase III clinical study-Carrelizumab combined with apatinib for the treatment of advanced liver cancer The international multi-center phase III study has completed overseas enrollment, and initiated preparations for submission of the US FDA BLA/NDA
.
.
The first international multi-center phase III clinical study-Carrelizumab combined with apatinib for the treatment of advanced liver cancer The international multi-center phase III study has completed overseas enrollment, and initiated preparations for submission of the US FDA BLA/NDA
.
In addition, a number of R&D projects have been approved for clinical trials in Europe, Australia, South Korea and other countries and regions to carry out clinical trials
.
SHR-A1811, INS068, HRS4800, SHR-1819, SHR-1707, HR17031 and other products have successfully achieved global simultaneous development
.
.
SHR-A1811, INS068, HRS4800, SHR-1819, SHR-1707, HR17031 and other products have successfully achieved global simultaneous development
.
It can be seen from this that, facing the challenges and opportunities of high-quality development, innovation and upgrading, Hengrui Medicine is gradually moving from “Me-too” and “Me-better” in the initial stage of innovation to source innovation.
Targets such as IL-17A and URAT-1 are actively forward-looking layout, and are in the world's first echelon in the development of innovative targets such as SHR1403 (c-Met) and SHR-1701 (PD-L1/TGF-β)
.
Targets such as IL-17A and URAT-1 are actively forward-looking layout, and are in the world's first echelon in the development of innovative targets such as SHR1403 (c-Met) and SHR-1701 (PD-L1/TGF-β)
.
The industry generally believes that under the new market situation, China’s leading pharmaceutical innovation companies will inevitably face international competition, and they will also encounter more powerful competitors.
They will continue to invest heavily in R&D, which will further become pharmaceutical companies in the medium and long term.
Bring motivation for sustainable development
.
They will continue to invest heavily in R&D, which will further become pharmaceutical companies in the medium and long term.
Bring motivation for sustainable development
.
The R&D pipeline situation disclosed in Hengrui's semi-annual report
Pharmaceutical Network News, August 20, on the evening of August 19, Hengrui Pharmaceuticals released the 2021 semi-annual report.
The report showed that Hengrui Pharmaceuticals invested more than 2.
58 billion yuan in R&D in the first half of this year, an increase of 38.
48% year-on-year, and the proportion of R&D investment in sales revenue reached 19.
41%, a record high
.
The report showed that Hengrui Pharmaceuticals invested more than 2.
58 billion yuan in R&D in the first half of this year, an increase of 38.
48% year-on-year, and the proportion of R&D investment in sales revenue reached 19.
41%, a record high
.
At the same time, in this financial report, Hengrui Pharmaceuticals fully disclosed its latest product pipeline, covering the main clinical R&D pipelines of listed innovative drugs, the main clinical R&D pipelines of innovative drugs under research, and the main clinical R&D pipelines of overseas innovative drugs.
More than 240 clinical projects have been carried out at home and abroad,” and other information has attracted the attention of the industry
.
More than 240 clinical projects have been carried out at home and abroad,” and other information has attracted the attention of the industry
.
In the first half of this year, Hengrui Pharmaceuticals officially entered a critical transition period for the business sector to migrate from generic drugs to innovative drugs
.
After experiencing the decline in the sales of generic drugs purchased in large quantities and the heavy test of innovative drugs and medical insurance negotiations, Sun Piaoyang took charge of the “second time”.
The industry is very concerned about the next development trend of Hengrui Medicine.
The product pipeline shown in the content of the semi-annual report With investment in research and development, the market has already made the market feel the determination of Hengrui Pharmaceuticals in the new stage of innovation and internationalization
.
.
After experiencing the decline in the sales of generic drugs purchased in large quantities and the heavy test of innovative drugs and medical insurance negotiations, Sun Piaoyang took charge of the “second time”.
The industry is very concerned about the next development trend of Hengrui Medicine.
The product pipeline shown in the content of the semi-annual report With investment in research and development, the market has already made the market feel the determination of Hengrui Pharmaceuticals in the new stage of innovation and internationalization
.
Hengrui's "drawer" is opening
"Whether it is a small molecule or a large molecule, Hengrui's innovative drugs are far ahead in terms of the number of research and development and the speed of clinical advancement.
More importantly, you can't guess how much Sun Piaoyang and Hengrui have hidden in their drawers.
New medicine!" At the end of 2020, the market value of Hengrui Pharmaceuticals exceeded 600 billion yuan.
At a medical innovation research and development conference, a guest expressed such emotion
.
More importantly, you can't guess how much Sun Piaoyang and Hengrui have hidden in their drawers.
New medicine!" At the end of 2020, the market value of Hengrui Pharmaceuticals exceeded 600 billion yuan.
At a medical innovation research and development conference, a guest expressed such emotion
.
When it comes to the transformation and upgrading of local medicines and R&D innovation, Hengrui Pharmaceuticals is an existence that cannot be ignored
.
However, in 2021, faced with the pressure of high-volume procurement competition and the "clinical value" of local pharmaceutical innovation, Hengrui's stock price fluctuated and dropped, and its market value evaporated by more than 200 billion yuan in just six months
.
.
However, in 2021, faced with the pressure of high-volume procurement competition and the "clinical value" of local pharmaceutical innovation, Hengrui's stock price fluctuated and dropped, and its market value evaporated by more than 200 billion yuan in just six months
.
Today, the entire industry is undergoing the test of ecological changes in the pharmaceutical industry and adapting to the new market rules under the new normal
.
Facing the fierce competition brought about by the normalization of mass purchases, the medical insurance payment system reform and the pressure of increasing the volume of drugs after price negotiations , many pharmaceutical companies are facing the same market pressure as Hengrui Pharmaceuticals
.
.
Facing the fierce competition brought about by the normalization of mass purchases, the medical insurance payment system reform and the pressure of increasing the volume of drugs after price negotiations , many pharmaceutical companies are facing the same market pressure as Hengrui Pharmaceuticals
.
As described by Hengrui Medicine in this semi-annual report, since 2018, the company has entered the country to purchase a total of 28 varieties of generic drugs.
18 varieties have been selected.
The average price of the selected products has dropped by 72.
6%, which has caused the company's performance.
Greater pressure
.
At the same time, the domestic innovative biopharmaceutical industry is facing serious homogeneity competition, and the costs of research and development, manpower, and production are rising rapidly, and biomedical innovation is facing severe challenges
.
18 varieties have been selected.
The average price of the selected products has dropped by 72.
6%, which has caused the company's performance.
Greater pressure
.
At the same time, the domestic innovative biopharmaceutical industry is facing serious homogeneity competition, and the costs of research and development, manpower, and production are rising rapidly, and biomedical innovation is facing severe challenges
.
As a leader in the transformation and innovation and upgrading of China's pharmaceutical industry, concentrating resources to achieve rapid breakthroughs in innovation and internationalization is a solution considered by Hengrui Pharmaceuticals and an inevitable choice for the medium and long-term development of the company
.
.
In fact, Hengrui Pharmaceutical’s annual R&D investment in 2020 will be close to 5 billion yuan, and the proportion of R&D in revenue is rapidly approaching the level of multinational pharmaceutical companies.
According to the current rhythm of R&D and innovation of enterprises, large-scale R&D investment continues to promote, so Hengrui Medicine achieved results in the first half of this year
.
According to the current rhythm of R&D and innovation of enterprises, large-scale R&D investment continues to promote, so Hengrui Medicine achieved results in the first half of this year
.
The semi-annual report shows that in the first half of this year, Hengrui Pharmaceuticals obtained 5 production approvals for innovative drug preparations, 9 production approvals for generic pharmaceutical preparations, 41 drug clinical approvals, and obtained consistency evaluation approvals for 10 varieties, and completed the agreement of 2 products.
More than 240 clinical projects are being carried out at home and abroad; 131 new domestic patent applications and 39 new international PCT applications have been submitted, 64 domestic authorizations and 59 foreign authorizations have been obtained
.
More than 240 clinical projects are being carried out at home and abroad; 131 new domestic patent applications and 39 new international PCT applications have been submitted, 64 domestic authorizations and 59 foreign authorizations have been obtained
.
Speed up the process of internationalization
Focusing on the topic of the internationalization of China’s pharmaceutical industry, Chinese companies and pharmaceutical products must not only “bring in” but also “go out”.
How to sell outstanding Chinese-developed drugs to overseas markets is something that large domestic pharmaceutical companies are thinking about.
And explore the development path
.
How to sell outstanding Chinese-developed drugs to overseas markets is something that large domestic pharmaceutical companies are thinking about.
And explore the development path
.
Internationalization is the strategic direction Hengrui has adhered to for many years
.
In the first half of this year, Hengrui Medicine’s overseas R&D expenditure totaled 643 million yuan, and the pace of building an international clinical R&D team and deploying international clinical trials of innovative drugs has been accelerating
.
The company has established a complete clinical R&D team covering medical science, clinical operations, registration, pharmacology, statistics, quality management, pharmacovigilance and other departments in the United States and Europe, and has achieved high-efficiency operation and high-quality execution of research projects At present, the company has a total of 136 overseas R&D teams, including 95 in the US team and 31 in the European team
.
.
In the first half of this year, Hengrui Medicine’s overseas R&D expenditure totaled 643 million yuan, and the pace of building an international clinical R&D team and deploying international clinical trials of innovative drugs has been accelerating
.
The company has established a complete clinical R&D team covering medical science, clinical operations, registration, pharmacology, statistics, quality management, pharmacovigilance and other departments in the United States and Europe, and has achieved high-efficiency operation and high-quality execution of research projects At present, the company has a total of 136 overseas R&D teams, including 95 in the US team and 31 in the European team
.
In terms of specific projects, in the first half of this year, Hengrui Medicine received 3 FDA clinical approvals, including fluzoparib capsules combined with abiraterone acetate tablets and prednisone tablets (AA-P) compared to placebo combined with AA-P as first-line treatment An international multi-center phase III study of metastatic castration-resistant prostate cancer, a multi-cohort, open phase II study of carrelizumab combined with famitinib in the treatment of advanced solid tumors, and evaluation of the pharmacodynamics of HR17031 injection, Phase I study of pharmacokinetics, safety and tolerability
.
The first international multi-center phase III clinical study-Carrelizumab combined with apatinib for the treatment of advanced liver cancer The international multi-center phase III study has completed overseas enrollment, and initiated preparations for submission of the US FDA BLA/NDA
.
.
The first international multi-center phase III clinical study-Carrelizumab combined with apatinib for the treatment of advanced liver cancer The international multi-center phase III study has completed overseas enrollment, and initiated preparations for submission of the US FDA BLA/NDA
.
In addition, a number of R&D projects have been approved for clinical trials in Europe, Australia, South Korea and other countries and regions to carry out clinical trials
.
SHR-A1811, INS068, HRS4800, SHR-1819, SHR-1707, HR17031 and other products have successfully achieved global simultaneous development
.
.
SHR-A1811, INS068, HRS4800, SHR-1819, SHR-1707, HR17031 and other products have successfully achieved global simultaneous development
.
It can be seen from this that, facing the challenges and opportunities of high-quality development, innovation and upgrading, Hengrui Medicine is gradually moving from “Me-too” and “Me-better” in the initial stage of innovation to source innovation.
Targets such as IL-17A and URAT-1 are actively forward-looking layout, and are in the world's first echelon in the development of innovative targets such as SHR1403 (c-Met) and SHR-1701 (PD-L1/TGF-β)
.
Targets such as IL-17A and URAT-1 are actively forward-looking layout, and are in the world's first echelon in the development of innovative targets such as SHR1403 (c-Met) and SHR-1701 (PD-L1/TGF-β)
.
The industry generally believes that under the new market situation, China’s leading pharmaceutical innovation companies will inevitably face international competition, and they will also encounter more powerful competitors.
They will continue to invest heavily in R&D, which will further become pharmaceutical companies in the medium and long term.
Bring motivation for sustainable development
.
They will continue to invest heavily in R&D, which will further become pharmaceutical companies in the medium and long term.
Bring motivation for sustainable development
.
The R&D pipeline situation disclosed in Hengrui's semi-annual report
Pharmaceutical Network News, August 20, on the evening of August 19, Hengrui Pharmaceuticals released the 2021 semi-annual report.
The report showed that Hengrui Pharmaceuticals invested more than 2.
58 billion yuan in R&D in the first half of this year, an increase of 38.
48% year-on-year, and the proportion of R&D investment in sales revenue reached 19.
41%, a record high
.
The report showed that Hengrui Pharmaceuticals invested more than 2.
58 billion yuan in R&D in the first half of this year, an increase of 38.
48% year-on-year, and the proportion of R&D investment in sales revenue reached 19.
41%, a record high
.
At the same time, in this financial report, Hengrui Pharmaceuticals fully disclosed its latest product pipeline, covering the main clinical R&D pipelines of listed innovative drugs, the main clinical R&D pipelines of innovative drugs under research, and the main clinical R&D pipelines of overseas innovative drugs.
More than 240 clinical projects have been carried out at home and abroad,” and other information has attracted the attention of the industry
.
More than 240 clinical projects have been carried out at home and abroad,” and other information has attracted the attention of the industry
.
In the first half of this year, Hengrui Pharmaceuticals officially entered a critical transition period for the business sector to migrate from generic drugs to innovative drugs
.
After experiencing the decline in the sales of generic drugs purchased in large quantities and the heavy test of innovative drugs and medical insurance negotiations, Sun Piaoyang took charge of the “second time”.
The industry is very concerned about the next development trend of Hengrui Medicine.
The product pipeline shown in the content of the semi-annual report With investment in research and development, the market has already made the market feel the determination of Hengrui Pharmaceuticals in the new stage of innovation and internationalization
.
.
After experiencing the decline in the sales of generic drugs purchased in large quantities and the heavy test of innovative drugs and medical insurance negotiations, Sun Piaoyang took charge of the “second time”.
The industry is very concerned about the next development trend of Hengrui Medicine.
The product pipeline shown in the content of the semi-annual report With investment in research and development, the market has already made the market feel the determination of Hengrui Pharmaceuticals in the new stage of innovation and internationalization
.
Hengrui's "drawer" is opening
Hengrui's "drawer" is opening "Whether it is a small molecule or a large molecule, Hengrui's innovative drugs are far ahead in terms of the number of research and development and the speed of clinical advancement.
More importantly, you can't guess how much Sun Piaoyang and Hengrui have hidden in their drawers.
New medicine!" At the end of 2020, the market value of Hengrui Pharmaceuticals exceeded 600 billion yuan.
At a medical innovation research and development conference, a guest expressed such emotion
.
More importantly, you can't guess how much Sun Piaoyang and Hengrui have hidden in their drawers.
New medicine!" At the end of 2020, the market value of Hengrui Pharmaceuticals exceeded 600 billion yuan.
At a medical innovation research and development conference, a guest expressed such emotion
.
When it comes to the transformation and upgrading of local medicines and R&D innovation, Hengrui Pharmaceuticals is an existence that cannot be ignored
.
However, in 2021, faced with the pressure of high-volume procurement competition and the "clinical value" of local pharmaceutical innovation, Hengrui's stock price fluctuated and dropped, and its market value evaporated by more than 200 billion yuan in just six months
.
.
However, in 2021, faced with the pressure of high-volume procurement competition and the "clinical value" of local pharmaceutical innovation, Hengrui's stock price fluctuated and dropped, and its market value evaporated by more than 200 billion yuan in just six months
.
Today, the entire industry is undergoing the test of ecological changes in the pharmaceutical industry and adapting to the new market rules under the new normal
.
Facing the fierce competition brought about by the normalization of mass purchases, the medical insurance payment system reform and the pressure of increasing the volume of drugs after price negotiations , many pharmaceutical companies are facing the same market pressure as Hengrui Pharmaceuticals
.
Drugs Drugs Drugs Pharmaceutical companies Pharmaceutical pharmaceutical business enterprises.
Facing the fierce competition brought about by the normalization of mass purchases, the medical insurance payment system reform and the pressure of increasing the volume of drugs after price negotiations , many pharmaceutical companies are facing the same market pressure as Hengrui Pharmaceuticals
.
As described by Hengrui Medicine in this semi-annual report, since 2018, the company has entered the country to purchase a total of 28 varieties of generic drugs.
18 varieties have been selected.
The average price of the selected products has dropped by 72.
6%, which has caused the company's performance.
Greater pressure
.
At the same time, the domestic innovative biopharmaceutical industry is facing serious homogeneity competition, and the costs of research and development, manpower, and production are rising rapidly, and biomedical innovation is facing severe challenges
.
Procurement Procurement Procurement18 varieties have been selected.
The average price of the selected products has dropped by 72.
6%, which has caused the company's performance.
Greater pressure
.
At the same time, the domestic innovative biopharmaceutical industry is facing serious homogeneity competition, and the costs of research and development, manpower, and production are rising rapidly, and biomedical innovation is facing severe challenges
.
As a leader in the transformation and innovation and upgrading of China's pharmaceutical industry, concentrating resources to achieve rapid breakthroughs in innovation and internationalization is a solution considered by Hengrui Pharmaceuticals and an inevitable choice for the medium and long-term development of the company
.
.
In fact, Hengrui Pharmaceutical’s annual R&D investment in 2020 will be close to 5 billion yuan, and the proportion of R&D in revenue is rapidly approaching the level of multinational pharmaceutical companies.
According to the current rhythm of R&D and innovation of enterprises, large-scale R&D investment continues to promote, so Hengrui Medicine achieved results in the first half of this year
.
According to the current rhythm of R&D and innovation of enterprises, large-scale R&D investment continues to promote, so Hengrui Medicine achieved results in the first half of this year
.
The semi-annual report shows that in the first half of this year, Hengrui Pharmaceuticals obtained 5 production approvals for innovative drug preparations, 9 production approvals for generic pharmaceutical preparations, 41 drug clinical approvals, and obtained consistency evaluation approvals for 10 varieties, and completed the agreement of 2 products.
More than 240 clinical projects are being carried out at home and abroad; 131 new domestic patent applications and 39 new international PCT applications have been submitted, 64 domestic authorizations and 59 foreign authorizations have been obtained
.
More than 240 clinical projects are being carried out at home and abroad; 131 new domestic patent applications and 39 new international PCT applications have been submitted, 64 domestic authorizations and 59 foreign authorizations have been obtained
.
Speed up the process of internationalization
Speed up the process of internationalization Focusing on the topic of the internationalization of China’s pharmaceutical industry, Chinese companies and pharmaceutical products must not only “bring in” but also “go out”.
How to sell outstanding Chinese-developed drugs to overseas markets is something that large domestic pharmaceutical companies are thinking about.
And explore the development path
.
How to sell outstanding Chinese-developed drugs to overseas markets is something that large domestic pharmaceutical companies are thinking about.
And explore the development path
.
Internationalization is the strategic direction Hengrui has adhered to for many years
.
In the first half of this year, Hengrui Medicine’s overseas R&D expenditure totaled 643 million yuan, and the pace of building an international clinical R&D team and deploying international clinical trials of innovative drugs has been accelerating
.
The company has established a complete clinical R&D team covering medical science, clinical operations, registration, pharmacology, statistics, quality management, pharmacovigilance and other departments in the United States and Europe, and has achieved high-efficiency operation and high-quality execution of research projects At present, the company has a total of 136 overseas R&D teams, including 95 in the US team and 31 in the European team
.
.
In the first half of this year, Hengrui Medicine’s overseas R&D expenditure totaled 643 million yuan, and the pace of building an international clinical R&D team and deploying international clinical trials of innovative drugs has been accelerating
.
The company has established a complete clinical R&D team covering medical science, clinical operations, registration, pharmacology, statistics, quality management, pharmacovigilance and other departments in the United States and Europe, and has achieved high-efficiency operation and high-quality execution of research projects At present, the company has a total of 136 overseas R&D teams, including 95 in the US team and 31 in the European team
.
In terms of specific projects, in the first half of this year, Hengrui Medicine received 3 FDA clinical approvals, including fluzoparib capsules combined with abiraterone acetate tablets and prednisone tablets (AA-P) compared to placebo combined with AA-P as first-line treatment An international multi-center phase III study of metastatic castration-resistant prostate cancer, a multi-cohort, open phase II study of carrelizumab combined with famitinib in the treatment of advanced solid tumors, and evaluation of the pharmacodynamics of HR17031 injection, Phase I study of pharmacokinetics, safety and tolerability
.
The first international multi-center phase III clinical study-Carrelizumab combined with apatinib for the treatment of advanced liver cancer The international multi-center phase III study has completed overseas enrollment, and initiated preparations for submission of the US FDA BLA/NDA
.
.
The first international multi-center phase III clinical study-Carrelizumab combined with apatinib for the treatment of advanced liver cancer The international multi-center phase III study has completed overseas enrollment, and initiated preparations for submission of the US FDA BLA/NDA
.
In addition, a number of R&D projects have been approved for clinical trials in Europe, Australia, South Korea and other countries and regions to carry out clinical trials
.
SHR-A1811, INS068, HRS4800, SHR-1819, SHR-1707, HR17031 and other products have successfully achieved global simultaneous development
.
.
SHR-A1811, INS068, HRS4800, SHR-1819, SHR-1707, HR17031 and other products have successfully achieved global simultaneous development
.
It can be seen from this that, facing the challenges and opportunities of high-quality development, innovation and upgrading, Hengrui Medicine is gradually moving from “Me-too” and “Me-better” in the initial stage of innovation to source innovation.
Targets such as IL-17A and URAT-1 are actively forward-looking layout, and are in the world's first echelon in the development of innovative targets such as SHR1403 (c-Met) and SHR-1701 (PD-L1/TGF-β)
.
Targets such as IL-17A and URAT-1 are actively forward-looking layout, and are in the world's first echelon in the development of innovative targets such as SHR1403 (c-Met) and SHR-1701 (PD-L1/TGF-β)
.
The industry generally believes that under the new market situation, China’s leading pharmaceutical innovation companies will inevitably face international competition, and they will also encounter more powerful competitors.
They will continue to invest heavily in R&D, which will further become pharmaceutical companies in the medium and long term.
Bring motivation for sustainable development
.
They will continue to invest heavily in R&D, which will further become pharmaceutical companies in the medium and long term.
Bring motivation for sustainable development
.
The R&D pipeline situation disclosed in Hengrui's semi-annual report
The R&D pipeline situation disclosed in Hengrui's semi-annual report 
